Sweeting MJ - Search Results

1

A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data.

Wheeler GM, Sweeting MJ, Mander AP. Wheeler GM, et al. Among authors: sweeting mj. J R Stat Soc Ser C Appl Stat. 2019 Feb;68(2):309-329. doi: 10.1111/rssc.12323. Epub 2018 Nov 22. J R Stat Soc Ser C Appl Stat. 2019. PMID: 30880843 Free PMC article.

2

Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.

Mander AP, Wason JM, Sweeting MJ, Thompson SG. Mander AP, et al. Among authors: sweeting mj. Pharm Stat. 2012 Mar-Apr;11(2):91-6. doi: 10.1002/pst.501. Epub 2012 Jan 10. Pharm Stat. 2012. PMID: 22232071

3

Escalation strategies for combination therapy Phase I trials.

Sweeting MJ, Mander AP. Sweeting MJ, et al. Pharm Stat. 2012 May-Jun;11(3):258-66. doi: 10.1002/pst.1497. Epub 2012 Mar 12. Pharm Stat. 2012. PMID: 22411472 Free PMC article.

4

Making predictions from complex longitudinal data, with application to planning monitoring intervals in a national screening programme.

Sweeting MJ, Thompson SG. Sweeting MJ, et al. J R Stat Soc Ser A Stat Soc. 2012 Apr;175(2):569-586. doi: 10.1111/j.1467-985X.2011.01005.x. J R Stat Soc Ser A Stat Soc. 2012. PMID: 22879705 Free PMC article.

5

Adaptive designs for dual-agent phase I dose-escalation studies.

Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI. Harrington JA, et al. Among authors: sweeting mj. Nat Rev Clin Oncol. 2013 May;10(5):277-88. doi: 10.1038/nrclinonc.2013.35. Epub 2013 Mar 19. Nat Rev Clin Oncol. 2013. PMID: 23507740 Review.

6

Fully Bayesian hierarchical modelling in two stages, with application to meta-analysis.

Lunn D, Barrett J, Sweeting M, Thompson S. Lunn D, et al. J R Stat Soc Ser C Appl Stat. 2013 Aug;62(4):551-572. doi: 10.1111/rssc.12007. J R Stat Soc Ser C Appl Stat. 2013. PMID: 24223435 Free PMC article.

7

A product of independent beta probabilities dose escalation design for dual-agent phase I trials.

Mander AP, Sweeting MJ. Mander AP, et al. Among authors: sweeting mj. Stat Med. 2015 Apr 15;34(8):1261-76. doi: 10.1002/sim.6434. Epub 2015 Jan 29. Stat Med. 2015. PMID: 25630638 Free PMC article.

8

Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.

Wheeler GM, Sweeting MJ, Mander AP, Lee SM, Cheung YK. Wheeler GM, et al. Among authors: sweeting mj. Stat Med. 2017 Jan 30;36(2):225-241. doi: 10.1002/sim.6912. Epub 2016 Feb 19. Stat Med. 2017. PMID: 26891942 Free PMC article.

9

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.

Wheeler GM, Sweeting MJ, Mander AP. Wheeler GM, et al. Among authors: sweeting mj. PLoS One. 2016 Jul 12;11(7):e0159026. doi: 10.1371/journal.pone.0159026. eCollection 2016. PLoS One. 2016. PMID: 27403961 Free PMC article.

10

Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.

Wheeler GM, Sweeting MJ, Mander AP. Wheeler GM, et al. Among authors: sweeting mj. Stat Med. 2017 Jul 20;36(16):2499-2513. doi: 10.1002/sim.7280. Epub 2017 Mar 15. Stat Med. 2017. PMID: 28295513 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters